Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
Article
Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Article
Google Scholar
Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2019;74(1):135–45.
Article
Google Scholar
Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med. 2004;164(11):1227–30.
Article
Google Scholar
Lee TH, Kantoff PW, McNaughton-Collins MF. Screening for prostate cancer. N Engl J Med. 2009;360(13): e18.
Article
CAS
Google Scholar
Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595–605.
Article
CAS
Google Scholar
Welch HG, Albertsen PC. Reconsidering prostate cancer mortality—the future of PSA screening. N Engl J Med. 2020;382(16):1557–63.
Article
Google Scholar
Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening—a perspective on the current state of the evidence. N Engl J Med. 2017;376(13):1285–9.
Article
Google Scholar
Gretzer MB. Partin AWJEUS: PSA levels and the probability of prostate cancer on biopsy. Eur Urol Suppl. 2002;1(6):21–7.
Article
Google Scholar
Bibbins-Domingo K, Grossman DC, Curry SJ. The US preventive services task force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA. 2017;317(19):1949–50.
Article
Google Scholar
Nakano Y, Okamura K, Takamura S, Okamoto N. Nagasaka TJIJoU: measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4–20 ng/mL. Int J Urol. 2010;12(8):721–7.
Article
Google Scholar
Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: a meta-analysis. Medicine (Baltimore). 2018;97(13):e0249.
Article
CAS
Google Scholar
Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(1):12–9.
Article
CAS
Google Scholar
Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018;174(6):1347–60.
Article
CAS
Google Scholar
Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20(7):404–16.
Article
CAS
Google Scholar
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.
Article
CAS
Google Scholar
Zeng S, Ying Y, Xing N, Wang B, Qian Z, Zhou Z, Zhang Z, Xu W, Wang H, Dai L, et al. Noninvasive detection of urothelial carcinoma by cost-effective low-coverage whole-genome sequencing from urine-exfoliated cell DNA. Clin Cancer Res. 2020;26(21):5646–54.
Article
CAS
Google Scholar
Feng S, Ding Z, Wang J, Qian Z, Li S, Zhang C, Xin H, Liu S, Ding G, Hu M, et al. Investigation of plasma cell-free cancer genome chromosomal instability as a tool for targeted minimally invasive biomarkers for primary liver cancer diagnoses. Cancer Med. 2020;9(14):5075–85.
Article
CAS
Google Scholar
Zhou H, Wang XJ, Jiang X, Qian Z, Chen T, Hu Y, Chen ZH, Gao Y, Wang R, Ye WW, et al. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse. Breast Cancer Res Treat. 2019;178(1):63–73.
Article
CAS
Google Scholar
Wang X, Fu XH, Qian ZL, Zhao T, Duan AQ, Ruan X, Zhu B, Yin L, Zhang YJ, Yu WL. Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: a prospective cohort study. Transl Oncol. 2021;14(1):100908.
Article
Google Scholar
Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.
Article
Google Scholar
Wang X, Grasso CS, Jordahl KM, Kolb S, Nyame YA, Wright JL, Ostrander EA, Troyer DA, Lance R, Feng Z, et al. Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(3):494–506.
Article
CAS
Google Scholar
Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci USA. 2019;116(23):11390–5.
Article
CAS
Google Scholar
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. Genome project data processing S: the sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078–9.
Article
Google Scholar
Seshan VE, Olshen A. DNAcopy: DNA copy number data analysis. R package version 1530. 2017.
Guo J, Yang J, Zhang X, Feng X, Zhang H, Chen L, Johnson H, Persson JL, Xiao K. A panel of biomarkers for diagnosis of prostate cancer using urine samples. Anticancer Res. 2018;38(3):1471–7.
CAS
PubMed
Google Scholar
Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101(5):894–904.
Article
CAS
Google Scholar
Kotwal AA, Schumm P, Mohile SG, Dale W. The influence of stress, depression, and anxiety on PSA screening rates in a nationally representative sample. Med Care. 2012;50(12):1037–44.
Article
Google Scholar
Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. Urology. 2003;61(4):760–4.
Article
Google Scholar
Kuznetsova AY, Seget K, Moeller GK, de Pagter MS, de Roos JA, Durrbaum M, Kuffer C, Muller S, Zaman GJ, Kloosterman WP, et al. Chromosomal instability, tolerance of mitotic errors and multidrug resistance are promoted by tetraploidization in human cells. Cell Cycle. 2015;14(17):2810–20.
Article
CAS
Google Scholar
Bakhoum SF, Landau DA. Chromosomal instability as a driver of tumor heterogeneity and evolution. Cold Spring Harb Perspect Med. 2017;7(6):a029611.
Article
Google Scholar
Choyke PL, Loeb S. Active surveillance of prostate cancer. Oncology (Williston Park). 2017;31(1):67–70.
Google Scholar
Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127–33.
Article
CAS
Google Scholar
Russo G, Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Giordano A, Autran-Gomez A, Di Monaco F, Di Silverio F, Sale P, et al. p53 gene mutational rate, Gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation? J Med Virol. 2008;80(12):2100–7.
Article
CAS
Google Scholar